“…It has been used in a variety of clinical trials, including various populations of hypertensive patients such as diabetics, the elderly, patients with benign prostatic hyperplasia or hypercholesterolaemia, the obese or Afro-Americans and in combination with all major groups of antihypertensive drugs such as: calciumchannel antagonists, diuretics, β -adrenoreceptor antagonists, ACEIs and ARBs [4,7,[10][11][12]14,17,19,20,22,24,[43][44][45][46][47][48] . In these studies, doxazosin in either standard or GITS formulation was added as a second-or third-line agent.…”